01—Abstract
Summary
Summary of the 10-Q filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.
Merck & Co., Inc. reported its first-quarter 2025 financial results, showing a slight year-over-year decrease in total sales to $15.5 billiona from $15.8 billion in Q1 2024.
This decline was primarily driven by lower vaccine sales, particularly Gardasil/Gardasil 9, and reduced sales in the virology and immunology segments. However, the company saw growth in its oncology, cardiovascular, and diabetes franchises, supported by strong performance from Keytruda and the new cardiovascular drug Winrevair. Despite the overall sales dip, Merck's profitability improved, with Net Income increasing to $5.1 billionb from $4.8 billion year-over-year, leading to a rise in diluted Earnings Per Share (EPS) to $2.01 from $1.87.
Research and Development expenses saw a notable decrease, primarily due to a significant charge in the prior year related to the acquisition of Harpoon Therapeutics. The company also announced a new licensing agreement for an investigational oral small molecule Lipoprotein(a) inhibitor and acquired a manufacturing facility in Ireland, signaling continued strategic investment in its pipeline and operational capabilities.
02—Key points
Key Highlights
- Total sales decreased by 2% to $15.5 billion in Q1 2025, primarily due to a significant decline in Gardasil/Gardasil 9 sales and lower demand for Lagevrio.
- Net Income increased by 6.6% to $5.1 billion, and diluted EPS rose to $2.01 from $1.87 in the prior year's quarter.
- Keytruda continued its strong performance with global sales growing 4% to $7.2 billion, driven by increased utilization across various cancer indications.
- The new cardiovascular drug Winrevair showed strong uptake with $280 million in sales in its first full quarter post-launch.
- Research and Development expenses decreased by 9% to $3.6 billion, largely due to a substantial charge in Q1 2024 related to the Harpoon Therapeutics acquisition.
- Merck entered into a new exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor, for $200 million upfront plus potential milestones.
- The company acquired a manufacturing facility in Dundalk, Ireland, for $437 million to support its manufacturing network.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 2, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $15.53B$15.78B | −1.6% |
| Cost of Revenue | $3.42B$3.54B | −3.4% |
| Gross Profit | $12.11B$12.23B | −1.0% |
| R&D Expenses | $3.62B$3.99B | −9.3% |
| SG&A Expenses | $2.55B$2.48B | +2.8% |
| Net Income | $5.08B$4.76B | +6.7% |
| EPS (Basic) | $2.01$1.88 | +6.9% |
| EPS (Diluted) | $2.01$1.87 | +7.5% |
| Shares Outstanding (Basic) | 2.52B2.53B | −0.4% |
| Shares Outstanding (Diluted) | 2.53B2.54B | −0.5% |
05—Questions
Frequently Asked Questions
What was the primary driver of the sales decline in the first quarter of 2025?
The primary driver of the sales decline was a significant decrease in Gardasil/Gardasil 9 sales, largely due to lower demand in China and elevated channel inventory. Lower sales of Lagevrio and a decline in the immunology segment also contributed.
How did Merck's profitability change year-over-year?
Merck's profitability improved, with Net Income increasing to $5.1 billion from $4.8 billion in the first quarter of 2024. Diluted Earnings Per Share (EPS) also rose to $2.01 from $1.87.
What are Merck's key strategic developments in R&D and business development for Q1 2025?
Merck announced a new exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a) inhibitor, and acquired a manufacturing facility in Dundalk, Ireland. In R&D, Keytruda continues to expand its indications, and the company is advancing several other candidates including Welireg, Winrevair, and subcutaneous pembrolizumab.
What is the outlook for Keytruda sales?
Keytruda's global sales grew 4% in Q1 2025, reaching $7.2 billion. Growth was driven by increased demand in both U.S. and international markets across various earlier-stage and metastatic cancer indications. The company expects continued demand to support its growth.
06—Continue